Welcome Guest
Home » Reports » Cell Line Characterization Services Market, 2017-2027

Cell Line Characterization Services Market, 2017-2027

Published: Oct 20, 2017
Pages: 229
Product Code: RA10092
License Type :  (Learn More)

Cross contamination and cell line misidentification are some of the major concerns associated with the use of cell lines. According to published literature, cell lines used for scientific experiments are either misidentified or contaminated in approximately 15-25% cases. The use of such cell lines yields unreliable and irreproducible results, and leads to significant delays in research time lines and financial losses. The detrimental impact of using incorrect / misidentified cell lines poses a significant burden on the global healthcare budget. It has been estimated that a net loss of USD 28 billion is incurred every year on research that cannot be replicated due to the involvement of misidentified or contaminated cell lines in the US. Therefore, it is crucial to properly identify and authenticate cell lines used for research, both at the start of a project, as well as during the course of the study. To carry out cell line characterization, factors such as source of cell lines, their development history and the biological properties of cells determine the analytical tests required for characterization.

 

It is also worth highlighting that several regulatory authorities and scientific communities have undertaken different initiatives to spread awareness on the importance of cell line characterization. Various rules and standards have also been formulated, making it mandatory to characterize cell lines while submitting applications for marketing authorization, for receipt of grants / funds, or for publishing cell-based research in leading journals.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Cell Line Characterization Services Market, 2017-2027’ report features a comprehensive view on the current market landscape and future outlook of testing and / or authentication services for the characterization of cell lines. The report provides information on organizations that offer contract services for the characterization of cell lines. In addition to other elements, the report includes:

  • A discussion on the current market landscape of cell line characterization service providers (industry and non-industry players), along with information on their headquarters, type of cell lines characterized (mammalian, microbial, insect-derived, avian, marine and reptilian) and the testing services offered.
  • An analysis of the requirements established by various regulatory authorities, across different global regions, related to the characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines.
  • A comprehensive study on cell line authentication services, highlighting the need for such services. It features a brief historical overview, discussion on the contributions of key institutes / organizations involved in this domain, a list of awareness surveys conducted by various research groups, and a schematic world map representation depicting the most active geographies, in terms of the presence of cell line authentication service providers.
  • Profiles of biorepositories that offer testing services for characterization of cell lines; each profile features an overview of the repository and a brief description of its overall operations and cell line characterization services offered.
  • Profiles of key industry players that offer cell line characterization services. Each profile features an overview of the company, its financial performance, overall services portfolio, cell line characterization services, and an informed future outlook.
  • A detailed analysis of the database, featuring three schematic representations; these include a world map depicting the most active geographies (in terms of the presence of companies / organizations providing services for cell line characterization), a heat map featuring the distribution of companies on the basis of their location, number of employees and the source of cell lines and a spin wheel analysis of companies / organizations based on the number and type of tests offered, and location.

 

One of the key objectives of the report was to understand the existing market size and potential future growth opportunities within this domain. Based on parameters, such as number of projects involving the use of cell lines, source of cell lines, and cost of characterizing different types of cell lines, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2017-2027. To account for the uncertainties associated with the with the characterization of cell lines and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

 

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek (Managing Director, ARTES Biotechnology), Nienke Smits (Business Development, ModiQuest) and Oscar Hoogteijling (Business Development Manager, Bioceros). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. Over 135 organizations across the world are currently offering characterization services for cell lines to the biopharmaceutical industry and the research community. Of these, 55% of the service providers are industrial players while the rest are academic / research institutes / non-profit organizations.
  2. With the presence of 33 start-ups, 17 mid-sized and 17 large-sized firms, the current market landscape of industry players is highly fragmented. North America (~55%) and Europe (~30%) are considered to be the hubs for cell line testing services. Examples of start-ups working in this domain include (in alphabetical order) Accelero Bioanalytics, Avance Biosciences, Cell Guidance Systems, Cellaria, Endeavour DNA Laboratories, EuBiologics, Multiplexion, Oxford Genetics and Protein Technologies.
  3. Service providers offer a wide variety of testing services for different type cell lines; these include identity testing, sterility testing, genetic stability testing, and oncogenicity and tumorigenicity testing. Of these, identity testing or cell line authentication is the most popular type of service offered. Examples of companies that offer more than one type of service include (decreasing order of number of characterization tests) BioReliance, TFBS Bioscience, Activation Laboratories, Avance Biosciences, Charles River Laboratories, Eurofins Scientific, Livogen pharmed, Molecular Diagnostic Services, SGS and WuXi AppTec.
  4. Of the available identity testing methods, STR profiling has emerged as the current gold standard. In fact, over 80% of the academic players within this market offer this service. Examples include (in alphabetical order) Johns Hopkins School of Medicine, MD Anderson Cancer Center, Sanford Burnham Preby, University of Florida and University of Pittsburgh.
  5. Multiple biorepositories across the globe have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines; these include (in alphabetical order) American Type Cell Culture (US), Cell Bank Australia (Australia), Coriell Institute of Medical Research (US), Deutsche Sammlung von Mikroorganismen und Zellkulture (Germany) and Public Health England (UK). 
  6. Close to 88% of the contract service providers offer characterization services for mammalian cell lines. We also observed that around 26% service providers claim to have the necessary capabilities to characterize microbial cell lines, which are presently considered to be the second most popular type of in vitro model.
  7. Driven by the robust pipeline of biologics, launch of biosimilars, and increasing awareness within the research community on the use of authenticated cell lines, we expect the cell line characterization services market to witness double digit growth over the next decade. As the market evolves, mammalian cell lines are likely to remain the major focus of the overall cell line characterization services market (~82%) in 2027.  North America and Europe are likely to remain the primary cell line testing hubs in the coming decade.

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the cell line characterization market in the short-mid and long term.

 

Chapter 3 provides a general introduction to cell cultures and cell lines. It includes details related to the various types of cell lines, based on their sources of origin, and key characteristics, applications and concerns associated with their use in research. The chapter also outlines the general concepts of cell line characterization along with a detailed description of different types of testing methods used for such purposes. In addition, it also presents an opinion on the need for outsourcing cell line characterization activities.

 

Chapter 4 features comprehensive study on cell line authentication, highlighting the need for such services. The chapter presents a brief historical overview of how the process has evolved over the years, and the contributions of the ATCC, ICLAC database and GBSI cell authentication alliance related to cell line authentication. It also includes a list of general awareness surveys conducted by various research groups, and an analysis of the competitive landscape, highlighting the most active geographies, in terms of the presence of companies offering such services.

 

Chapter 5 presents information on the current regulatory landscape of the characterization of cell lines. The chapter highlights the role of various regulatory bodies, such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA) and World Health Organization (WHO), and the various regulatory standards and guidelines established / issued by them on the type of tests and general methods to use for the characterization and authentication of cell lines.

 

Chapter 6 provides details on the contract service providers that are actively offering cell line characterization services. The chapter includes information on their headquarters, and cell line characterization capabilities, including source of cell lines.

 

Chapter 7 features profiles of biorepositories that are playing an active role in providing cell line characterization services. Each profile provides a brief overview of the organization, and the cell line characterization services offered by them.

 

Chapter 8 features detailed profiles of the key industry players that are involved in providing services for the characterization of cell lines. Each profile includes a brief overview of the company, its financial performance, overall services portfolio, services offered related to cell line characterizationand a comprehensive future outlook.

 

Chapter 9 presents a comprehensive market forecast, highlighting the future potential of the market till 2027. The chapter provides detailed market segmentation based on type of cell lines (mammalian, microbial, insects and others), geographical regions (North America, Europe, Asia and rest of the world), type of organization (industry and non-industry), and stage of development (clinical and preclinical).

 

Chapter 10 is a compilation of key insights gathered from the study. It features a schematic representation on a world map, highlighting the key regional hubs offering cell line characterization services. Further, we have provided a heat map analysis of the distribution of companies involved in this field, based on their location (continent-wise distribution), number of employees and source of cell lines (mammalian, microbial, insect and avian). In addition, the chapter includes a spin wheel analysis of the distribution of industry players on the basis of their location, number of tests and type of tests (identity testing methods, sterility testing methods, stability testing methods and others) offered.

 

Chapter 11 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the current market scenario and trends that are likely to determine the future evolution of this segment of the biopharmaceutical industry.

 

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek (Managing Director, ARTES Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

 

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report. 

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cell Culture and Cell Lines
3.2.1. Types of Cell Culture
3.2.1.1. Primary Cell Culture
3.2.1.2. Secondary Cell Culture
3.2.2. Prerequisites for Using Cell Lines
3.2.3. Types of Cell lines
3.2.3.1. Finite Cell Lines
3.2.3.2. Continuous Cell Lines
3.2.3.3. Recombinant Cell Lines
3.2.3.4. Hybridoma Cell Lines
3.2.4. Sources of Cell Lines
3.2.4.1. Mammalian
3.2.4.2. Non-Mammalian
3.2.5. Applications of Cell Lines
3.2.6. Key Concerns Associated with Cell Lines
3.3. Cell Banks
3.3.1. Classification of Cell Banks
3.3.1.1. On the Basis of Tiers
3.3.1.2. On the Basis of GMP Status
3.4. Cell Line Characterization
3.4.1. Methods of Cell Line Characterization
3.4.1.1. Identity Testing
3.4.1.2. Sterility Testing
3.4.1.3. Genetic Stability Testing
3.5. Outsourcing of Cell Line Characterization Services
 
4. CELL LINE AUTHENTICATION
4.1. Chapter Overview
4.2. Need for Cell Line Authentication
4.3. Cell Line Authentication: Historical Timeline
4.4. Cell Line Authentication: Role of American Type Culture Collection (ATCC)
4.5. Cell Line Authentication: Role of International Cell Line Authentication Committee (ICLAC)
4.6. Cell Line Authentication: Role of Global Biological Standards Institute (GBSI)
4.7. Factors Contributing to Cell Line Misidentification
4.8. Awareness Surveys
4.9. STR Profiling Kits
4.10. Cell Line Authentication: Competitive Landscape
 
5. REGULATORY RECOMMENDATIONS AND GUIDELINES
5.1. Chapter Overview
5.2. Guidelines Issued by International Regulatory Agencies
5.2.1. World Health Organization (WHO)
5.2.2. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
5.3. Regulatory Guidelines for Cell Line Characterization in the US
5.4. Regulatory Guidelines for Cell Line Characterization in Europe
5.5. Regulatory Guidelines for Cell Line Characterization in Japan
 
 
6. COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Cell Line Characterization Service Providers: Market Landscape (Industry Players)
6.2.1. Distribution by Location
6.2.2. Distribution by Type of Cell Lines
6.2.3. Distribution by Type of Testing Methods
6.3. Cell Line Characterization Service Providers: Market Landscape (Non-Industry Players)
6.3.1. Distribution by Location
6.3.2. Distribution by Type of Cell Lines
6.3.3. Distribution by Type of Testing Methods
6.3.4. Distribution by Type of STR Kits
6.4. Cell Line Characterization Service Providers: Most Prominent Hubs
 
7. BIOREPOSITORIES
7.1. American Type Culture Collection 
7.1.1. Overview
7.1.2. Services Portfolio
7.1.3. Collaborations
7.2. Coriell Institute for Medical Research
7.2.1. Overview
7.2.2. Services Portfolio
7.3. European Collection of Authenticated Cell Cultures 
7.3.1. Overview
7.3.2. Services Portfolio
7.3.3. Collaborations
7.4. DSMZ
7.4.1. Overview
7.4.2. Services Portfolio
 
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. BioReliance (a Part of SAFC Commercial)
8.2.1. Company Overview
8.2.2. Services Portfolio
8.2.3. Future Outlook
 
8.3. Charles River Laboratories (CRL)
8.3.1. Company Overview
8.3.2. Financial Performance
8.3.3. Services Portfolio
8.3.4. Future Outlook
 
8.4. Cell Line Genetics
8.4.1. Company Overview
8.4.2. Services Portfolio
8.4.3. Future Outlook
 
8.5. Eurofins Scientific
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Services Portfolio
8.5.3.1. Services Offered by Eurofins Sinensis (The Netherlands)
8.5.3.2. Services Offered by Eurofins Lancaster Laboratories (US)
8.5.4. Future Outlook
 
8.6. Molecular Diagnostic Services
8.6.1. Company Overview
8.6.2. Services Portfolio
8.6.3. Future Outlook
 
8.7. SGS
8.7.1. Company Overview
8.7.2. Financial Performance
8.7.3. Services Portfolio
8.7.4. Future Outlook
 
8.8. Avance Biosciences
8.9. Biomeva (Acquired by AGC)
8.10. Creative Bioarray
8.11. Livogen Pharmed
8.12. MTI-GlobalStem (a Part of Thermo Fisher Scientific)
8.13. TFBS Bioscience
8.14. Waisman Biomanufacturing
8.15. WuXi AppTec
8.16. Other Players
8.16.1. ARTES Biotechnology
8.16.2. Bioceros
8.16.3. LakePharma
8.16.4. ModiQuest
 
9. MARKET OPPORTUNITY AND SIZING
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Input Data Tables and Assumptions
9.4. Cell Line Characterization Services Market Outlook, 2017-2027
9.4.1. Distribution of Future Opportunity by Type of Cell Lines
9.4.2. Distribution of Future Opportunity by Geography
9.4.3. Distribution of Future Opportunity by Type of Industry
9.4.4. Distribution of Future Opportunity by Stage of Development of Biologics
 
10. KEY INSIGHTS
10.1. Chapter Overview
10.2. Cell Line Characterization Service Providers: Regional Analysis
10.3. Cell Line Characterization Service Providers: Heat Map Analysis (Industry Players)
10.4. Cell Line Characterization Services: Spin Wheel Analysis (Industry Players)
 
11. CONCLUSION
11.1. Mishandling and Cross Contamination are the Root Causes of Cell Line Misidentification
11.2. Several Initiatives have been Launched by Various Organizations to Overcome such Challenges Associated with Cell Line Related R&D
11.3. Most Service Providers in this Domain Offer Services for the Characterization of Mammalian Cell Lines
11.4. STR Profiling is Considered to be the Current Gold Standard for Authentication of Cell Lines
11.5. Several Contract Service Providers have Added Significant Value Within this Market by Providing High-Quality Cell Line Characterization and Authentication Solutions
11.6. The Market Landscape Features a Mix of Both Industry and Non-Industry Players; the US and Europe are the Most Active Regional Hubs
11.7. Fostered by the Increased Demand for Cell Lines in Life Science Research, the Market is Likely to Witness Steady Growth in the Coming Decade
 
12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. Fan Chen, Vice President BioProcessing, LakePharma
12.3. Michael Pointek, Managing Director, ARTES Biotechnology
12.4. Nienke Smits, Business Development, ModiQuest
12.5. Oscar Hoogteijling, Business Development Manager, Bioceros
 
13. APPENDIX 1: TABULATED DATA
 
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS 
 
 
Figure 3.1 Primary and Secondary Cell Culture
 
Figure 3.2 Basic Process for Cell Line Generation
 
Figure 3.3 Recombinant Cell Line Development
 
Figure 3.4 Hybridoma Cell Line Development
 
Figure 3.5 Sources of Non-Mammalian Cell Lines
 
Figure 3.6 Applications of Cell Lines
 
Figure 3.7 Factors Affecting the Utility of Cell Lines
 
Figure 3.8 Process for Master and Working Cell Bank Production
 
Figure 3.9 Type of Testing Methods for Cell Line Characterization
 
Figure 3.10 Protocol for Karyotype Preparation
 
Figure 3.11 DNA Hybridization
 
Figure 3.12 DNA Fingerprinting
 
Figure 4.1 GBSI Cell Authentication Survey, 2015: Type of Authentication Tests
 
Figure 4.2 GBSI Cell Authentication Survey, 2015: Barriers to Cell Line Authentication
 
Figure 4.3 Cell Line Authentication: Historical Timeline
 
Figure 4.4 ICLAC Database: Distribution by Type of Cell Lines
 
Figure 4.5 Cell Line Authentication Service Providers
 
Figure 5.1 ICH Q5A (R1) Guidelines: Cell Bank Qualification
 
Figure 5.2 ICH Q5D Guidelines: Cell Bank Characterization
 
Figure 5.3 FDA Guidelines: Cell Bank Qualification
 
Figure 5.4 USP 63: Mycoplasma Detection in Cell Banks
 
Figure 5.5 CFR 610.18: Recommendations for Testing of Cell Lines
 
Figure 5.6 CFR 113.52: Recommendations for Testing of Cell Banks
 
Figure 5.7 EP 2.6.7: Recommendations for Mycoplasma Testing of Cell Banks
 
Figure 5.8 JP: Recommendations for Mycoplasma Testing of Cell Banks
 
Figure 6.1 Cell Line Characterization Service Providers (Industry Players): Distribution by Geography (Regions)
 
Figure 6.2 Cell Line Characterization Service Providers (Industry Players): Distribution by Geography (Countries)
 
Figure 6.3 Cell Line Characterization Service Providers (Industry Players): Distribution by Type of Cell Lines
 
Figure 6.4 Cell Line Characterization Service Providers (Industry Players): Distribution by Type of Testing Methods 
 
Figure 6.5 Cell Line Characterization Service Providers (Industry Players) Distribution by Type of Testing Methods (Individual Methods)
 
Figure 6.6 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location (Regions)
 
Figure 6.7 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location (Countries) 
 
Figure 6.8 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Lines 
 
Figure 6.9 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Testing Methods
 
Figure 6.10 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of STR Kits
 
Figure 6.11 Cell Line Characterization Services: North America, Contract Service Providers Logo Landscape
 
Figure 6.12 Cell Line Characterization Services: Europe, Contract Service Providers Logo Landscape
 
Figure 6.13 Cell Line Characterization Services: Asia Pacific, Contract Service Providers Logo Landscape
 
Figure 7.1 ATCC: Services Portfolio
 
Figure 7.2 Coriell Institute of Medical Research: Operating Segments 
 
Figure 7.3 Coriell Institute for Medical Research: Services Portfolio
 
Figure 7.4 ECACC: Biological Material Collection
 
Figure 7.5 ECACC: Segments Overview
 
Figure 7.6 DSMZ: History of Establishment and Expansion
 
Figure 7.7 DSMZ: Biological Material Collection
 
Figure 7.8 DSMZ: Cell Line Characterization Services
 
Figure 8.1 BioReliance: History
 
Figure 8.2 BioReliance: Services Portfolio
 
Figure 8.3 BioReliance: Cell Line Characterization Services
 
Figure 8.4 CRL: Business Segments Overview
 
Figure 8.5 CRL: Annual Revenues, FY 2012-H1 2017 (USD Billion)
 
Figure 8.6 CRL: Revenues by Business Segments, 2016 (USD Billion)
 
Figure 8.7 CRL: Services Portfolio
 
Figure 8.8 CRL: Cell Line Characterization Services: Overview
 
Figure 8.9 CRL: Testing Services for Cell Lines Derived from Different Species
 
Figure 8.10 CRL: Manufacturing and Characterization of Mammalian Cell Bank - Timeline
 
Figure 8.11 CRL: Manufacturing and Characterization of Microbial Cell Bank - Timeline
 
Figure 8.12 Eurofins Scientific: Annual Revenues, FY 2012-Q1 2017 (EUR Billion)
 
Figure 8.13 Eurofins Scientific: Revenues by Geography, 2016 (%)
 
Figure 8.14 Eurofins Sinensis: Services Portfolio
 
Figure 8.15 Eurofins Sinensis: Cell Line / Bank Characterization Services
 
Figure 8.16 Eurofins Lancaster Laboratories: Services Portfolio
 
Figure 8.17 Eurofins Lancaster Laboratories: Cell Line / Bank Characterization Services
 
Figure 8.18 Molecular Diagnostic Services: Services Portfolio
 
Figure 8.19 Molecular Diagnostic Services: Microbial Cell Bank Characterization Services
 
Figure 8.20 Molecular Diagnostic Services: Yeast Cell Bank Characterization Services
 
Figure 8.21 SGS: Annual Revenues, 2012-H1 2017 (CHF Billion)
 
Figure 8.22 SGS: Revenues by Geography, 2016 (%)
 
Figure 8.23 SGS: Services Portfolio
 
Figure 8.24 SGS: Segments Overview
 
Figure 8.25 SGS: Cell Line Characterization Services
 
Figure 9.1 Cell Line Characterization Services Market, 2017-2027 (USD Billion)
 
Figure 9.2 Cell Line Characterization Services Market, 2017-2027: Distribution by Type of Cell Lines (USD Billion)
 
Figure 9.3 Cell Line Characterization Services Market, 2017-2027: Distribution by Geographical Regions (USD Billion)
 
Figure 9.4 Cell Line Characterization Services Market, 2017-2027: Distribution by Type of Industry (USD Billion)
 
Figure 9.5 Cell Line Characterization Services Market, 2017-2027: Distribution by Stage of Development of Biologics (USD Billion)
 
Figure 10.1 Cell Line Characterization Service Providers: Regional Landscape
 
Figure 10.2 Cell Line Characterization Service Providers: Heat Map Analysis (Industry Players)
 
Figure 10.3 Cell Line Characterization Service Providers: Spin Wheel Analysis (Industry Players)
 
Figure 11.1 Overall Cell Line Characterization Services Market: Conservative, Base and Optimistic Scenarios, 2017, 2022 and 2027 (USD Billion)
 
 
Table 3.1 Comparison of Properties of Finite and Continuous Cell line
 
Table 3.2 Most Common Mammalian Cell Lines
 
Table 3.3 Human Cell Lines and Therapeutic Protein Products
 
Table 3.4 Cell Lines and Viral Vaccine Products
 
Table 4.1 List of Journals with Mandatory Requirement of Cell Line Authentication for Research Submissions
 
Table 4.2 ICLAC: Partner Organizations
 
Table 4.3 STR Profiling Kits
 
Table 5.1 WHO Recommendations: Cell Bank Characterization
 
Table 5.2 Regulatory Documents for Cell Line Characterization in the US
 
Table 5.3 USP 1050: Virus Testing in Cell Banks
 
Table 5.4 EP 5.2.3: Testing in Cell Banks
 
Table 6.1 Cell Line Characterization Service Providers (Industry Players): Distribution by Geography and Type of Cell Lines 
 
Table 6.2 Cell Line Characterization Service Providers (Industry Players): Distribution by Testing Methods
 
Table 6.3 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Geography and Type of Cell Lines 
 
Table 6.4 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Testing Methods
 
Table 7.1 ATCC: Overview
 
Table 7.2 ECACC: Overview
 
Table 7.3 DSMZ: Overview
 
Table 8.1 BioReliance: Company Overview 
 
Table 8.2 CRL: Company Overview
 
Table 8.3 Cell Line Genetics: Company Overview
 
Table 8.4 Cell Line Genetics: Testing Services for Cell Lines Derived from Different Species
 
Table 8.5 Eurofins Scientific: Company Overview
 
Table 8.6 Molecular Diagnostic Services: Company Overview
 
Table 8.7 Molecular Diagnostic Services: Mammalian Cell Bank Characterization Services
 
Table 8.8 SGS: Company Overview
 
Table 9.1 Input Data and Assumptions: Cost of Cell Line Characterization by Type and Grade of Cell Line
 
Table 9.2 Input Data and Assumptions: Distribution of Source of Cell Lines by Biopharmaceuticals Produced
 
Table 13.1 GBSI Cell Authentication Survey, 2015: Type of Authentication Tests
 
Table 13.2 GBSI Cell Authentication Survey, 2015: Barriers to Cell Line Authentication
 
Table 13.3 ICLAC Database: Distribution by Type of Cell Lines
 
Table 13.4 Cell Line Characterization Service Providers (Industry Players): Distribution by Location
 
Table 13.5 Cell Line Characterization Service Providers (Industry Players): Distribution by Type of Cell Lines
 
Table 13.6 Cell Line Characterization Service Providers (Industry Players): Distribution by Type of Testing Methods  
 
Table 13.7 Cell Line Characterization Service Providers (Industry Players) Distribution by Type of Testing Methods (Individual Methods)
 
Table 13.8 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location 
 
Table 13.9 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Lines
 
Table 13.10 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Testing Methods
 
Table 13.11 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of STR Kits
 
Table 13.12 CRL: Annual Revenues, FY 2012 – H1 2017 (USD Billion)
 
Table 13.13 CRL: Revenues by Business Segments, 2016 (USD Billion)
 
Table 13.14 Eurofins Scientific: Annual Revenues, FY 2012 – Q1 2017 (EUR Billion)
 
Table 13.15 Eurofins Scientific: Revenues by Geography, 2016 (%)
 
Table 13.16 SGS: Annual Revenues, 2012-H1 2017 (CHF Billion)
 
Table 13.17 SGS: Revenues by Geography, 2016 (%)
 
Table 13.18 Cell Line Characterization Services Market, 2017-2027: Conservative, Base and Optimistic Scenario (USD Billion)
 
Table 13.19 Cell Line Characterization Services Market, 2017-2027: Distribution by Type of Cell Lines (USD Billion)
 
Table 13.20 Cell Line Characterization Services Market, 2017-2027: Distribution by Geographical Regions (USD Billion)
 
Table 13.21 Cell Line Characterization Services Market, 2017-2027: Distribution by Type of Industry (USD Billion)
 
Table 13.22 Cell Line Characterization Services Market, 2017-2027: Distribution by Stage of Development of Biologics (USD Billion)
 
Table 13.23 Cell Line Characterization Services Market, 2017, 2022 and 2027: Conservative, Base and Optimistic Forecast Scenarios (USD Billion)
 

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. ABS
  3. Acambis
  4. Accelero Bioanalytics
  5. Actlabs
  6. Affymetrix
  7. Agilent Technologies
  8. Agilux Laboratories
  9. Alphora Research
  10. Ambry Genetics
  11. American National Standards Institute
  12. American Type Culture Collection
  13. Amgen
  14. Applied Biological Materials (abm)
  15. Applied Genetics Laboratories
  16. Applied Genomics Technology Center (AGTC), Wayne State University
  17. Applied StemCell (ASC)
  18. ARTES Biotechnology
  19. Australian Genome Research Facility
  20. Avance Biosciences
  21. BaseClear
  22. BEX
  23. Bioceros
  24. BioCrystal
  25. BIO-ENGINEERING
  26. Biogen
  27. BioMaxLab
  28. Biomay
  29. Biomedical Core Facility, Rappaport Faculty of Medicine, Technion Israel Institute of Technology
  30. BIOMEVA
  31. Bionique® Testing Laboratories
  32. BioOutsource (now part of Sartorius Stedim Biotech Group)
  33. Biopolymer/Genomics Core Facility, University of Maryland
  34. Biopremier
  35. BioReliance
  36. Bio-Synthesis
  37. Biovian
  38. Blue Stream Laboratories
  39. Cancer Research UK Cambridge Institute (CRUK CI)
  40. Cedars Sinai
  41. Cell Culture
  42. Cell Culture and Cytogenetics Facility, University of Pittsburgh
  43. Cell Guidance Systems
  44. Cell Line Genetics
  45. Cellaria
  46. CellBank Australia
  47. Cellonex
  48. Celsis International
  49. Center for Genetic Medicine (CGM), Northwestern Medicine
  50. Center for Genomic Medicine, National Cheng Kung University
  51. Central Illinois Grain Inspection
  52. Characterized Cell Line Core Facility, MD Anderson Cancer Center, The University of Texas
  53. Charles River Laboratories
  54. Clean Cells
  55. CLS Cell Line Service
  56. Coriell Institute for Medical Research
  57. Cosmo Genetech
  58. Covance
  59. Creative Bioarray (a division of Creative Dynamics)
  60. Cybrdi 
  61. Cytogenetics Research Core Laboratory, OHSU
  62. DDC Medical (a division of DNA Diagnostics Center)
  63. Department of Immunology, Genetics and Pathology, Uppsala University 
  64. Department of Molecular & Cell Biology (MCB), University of California
  65. Department of Molecular Medicine (MOMA), Aarhus University Hospital
  66. Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health
  67. DiagCor Bioscience
  68. Diagnostic Cytogenetics
  69. DNA Analysis Facility on Science Hill, Yale University
  70. DNA Core Facility, University of Missouri
  71. DNA Data Bank of Japan
  72. DNA Forensics Laboratory
  73. DNA Sequencing Core Facility, University of Utah
  74. DNA Sequencing Facility, Perelman School of Medicine, University of Pennsylvania
  75. DNA Sequencing Facility, The University of Manchester
  76. DNA True Test
  77. Drug Screening Rendered
  78. Duke Clinical and Translational Science Institute, Duke University
  79. Eli Lilly
  80. Endeavour DNA
  81. EuBiologics
  82. Eurofins Genomics
  83. Eurofins Lancaster Laboratories
  84. Eurofins Sinensis
  85. European Directorate for the Quality of Medicines and HealthCare (EDQM)
  86. European Medicines Agency
  87. European Molecular Biology Laboratory
  88. Friedrich-Loeffler-Institute
  89. Garvan Institute of Medical Research
  90. Gates Center for Regenerative Medicine, University of Colorado
  91. Genentech
  92. GENERI BIOTECH
  93. Genetic Resources Core Facility (GRCF), Johns Hopkins School of Medicine, Institute of Genetic Medicine
  94. Genetica DNA Laboratories
  95. Genomics Core Laboratory (GCL), Augusta University
  96. Genomics Core, Sanford Burnham Preby Medical Discovery Institute
  97. GenoSeq, UCLA Genotyping and Sequencing Core
  98. German Cancer Research Center (DKFZ)
  99. German Collection of Microorganisms and Cell Cultures (DSMZ)
  100. GlaxoSmithKline (GSK)
  101. Global Biological Standards Institute (GBSI)
  102. Harrison Research Laboratories
  103. Hy Laboratories
  104. IDEXX BioResearch
  105. ILC Micro-Chem
  106. Illumina
  107. IndoBiotek Services
  108. Institute for Molecular Medicine Finland (FIMM)
  109. Institute of Health and Biomedical Innovation, Genomics Research Facility, Queensland    University of Technology
  110. Integrated Systems Engineering
  111. Interdisciplinary Center for Biotechnology Research (ICBR), University of Florida
  112. International Cell Line Authentication Committee (ICLAC)
  113. Janssen Biotech
  114. KaryoLogic
  115. Laboratoire LCA
  116. LakePharma
  117. Laragen
  118. LGC Standards
  119. Li Ka Shing Faculty of Medicine, University of Hong Kong,
  120. Life Technologies
  121. Livogen pharmed
  122. Lonza
  123. MABION
  124. MaxCyte
  125. Merck
  126. Microbiology & Quality Associates
  127. Microsynth
  128. Ministry of Health, Labour and Welfare (MHRW)
  129. ModiQuest
  130. Molecular Biology Service Center, University of Colorado
  131. Molecular Cloning Laboratories (MCLAB)
  132. Molecular Cytogenetics Facility, MD Anderson Cancer Center, The University of Texas
  133. Molecular Diagnostic Services
  134. Monash Health Translation Precinct (MHTP) Medical Genomics Facility
  135. Moredun Scientific
  136. MTI-GlobalStem
  137. Multiplexion
  138. National Center for Biotechnology Information (NCBI)
  139. National Institute of Standards and Technology (NIST)
  140. National Institutes of Health (NIH)
  141. NorthGene
  142. Novartis
  143. Octapharma
  144. Oncotest
  145. Oxford Genetics
  146. Pharmaceutical and Food Safety Bureau (PFSB)
  147. Pharmaceuticals Medical Devices Agency (PMDA)
  148. ProBioGen
  149. Promega
  150. Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
  151. Protein Sciences
  152. Protein Technologies
  153. Public Health England (PHE)
  154. QED Bioscience
  155. qGenomics
  156. R M Nardone Associates
  157. Research Technology Support Facility (RTSF) Genomics Core, Michigan State University 
  158. Richter-Helm BioLogics
  159. RIKEN
  160. Rockland Immunochemicals
  161. Roswell Park Cancer Institute
  162. RUCDR Infinite Biologics
  163. Sanofi Pasteur
  164. SCIEX
  165. Sealy Center for Molecular Medicine, University of Texas Medical Branch
  166. Seqirus
  167. SGS
  168. Shannon McCormack Molecular Diagnostics Laboratory, Dana Farber Cancer Institute
  169. Shire
  170. Sigma-Aldrich
  171. Source BioScience
  172. Stem Cell and Transgenic Core Facility, College of Veterinary Medicine, Cornell University
  173. Stem Cell Core Facility, Institute of Molecular Biotechnology (IMBA), Austrian Academy of Sciences
  174. Sumitomo Dainippon Pharma
  175. Texcell
  176. TFBS Bioscience
  177. The Centre for Applied Genomics (TCAG), Genetic Analysis Facility, The Hospital for Sick Children
  178. The Institute for Forensic Genetics (IFG)
  179. The University of Texas Southwestern Medical Center
  180. The Westmead Institute for Medical Research
  181. Thermo Fisher  Scientific
  182. Tissue Culture Core facility, University of Texas Medical Branch (UTMB)
  183. Tissue Solutions
  184. Unit of High Technology (UAT), Vall d'Hebron Research Institute (VHIR)
  185. University of Arizona Genetics Core
  186. University of Leicester
  187. University of Sussex
  188. University of Vermont Cancer Center
  189. University of Washington
  190. USC Norris Comprehensive Cancer Center
  191. Valneva
  192. Vista Biologicals
  193. Vitrology
  194. Waisman Biomanufacturing
  195. Washington University Institute of Clinical and Translational Sciences (ICTS)
  196. Whittaker Corporation
  197. WiCell Research Institute
  198. WIL Research
  199. World Health Organization (WHO)
  200. WuXi AppTec
  201. WuXi Biologics 

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security